Analysts See $-0.07 EPS for OHR Pharmaceutical, Inc. (OHRP); Scholtz & Company Has Upped Edwards Lifesciences Corporati (EW) Holding

January 15, 2018 - By Adrian Mccoy

Scholtz & Company Llc increased Edwards Lifesciences Corporati (EW) stake by 11.05% reported in 2017Q3 SEC filing. Scholtz & Company Llc acquired 3,550 shares as Edwards Lifesciences Corporati (EW)’s stock rose 25.80%. The Scholtz & Company Llc holds 35,690 shares with $3.90 million value, up from 32,140 last quarter. Edwards Lifesciences Corporati now has $25.57 billion valuation. The stock increased 0.70% or $0.84 during the last trading session, reaching $120.83. About 1.03 million shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 15.41% since January 15, 2017 and is uptrending. It has underperformed by 1.29% the S&P500.

Analysts expect OHR Pharmaceutical, Inc. (NASDAQ:OHRP) to report $-0.07 EPS on February, 13.They anticipate $0.14 EPS change or 66.67% from last quarter’s $-0.21 EPS. After having $-0.08 EPS previously, OHR Pharmaceutical, Inc.’s analysts see -12.50% EPS growth. The stock increased 2.31% or $0.0074 during the last trading session, reaching $0.3281. About 2.77M shares traded or 13.82% up from the average. OHR Pharmaceutical, Inc. (NASDAQ:OHRP) has declined 77.87% since January 15, 2017 and is downtrending. It has underperformed by 94.57% the S&P500.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The company has market cap of $18.44 million. The Company’s lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. It currently has negative earnings. The firm is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion.

Investors sentiment increased to 1.44 in Q3 2017. Its up 0.19, from 1.25 in 2017Q2. It is positive, as 3 investors sold OHR Pharmaceutical, Inc. shares while 6 reduced holdings. 6 funds opened positions while 7 raised stakes. 4.60 million shares or 16.87% more from 3.93 million shares in 2017Q2 were reported. Vanguard holds 0% of its portfolio in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 1.13M shares. Renaissance Technologies Ltd Liability Corp owns 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 788,409 shares. Prelude Capital Management Limited Liability Co holds 0% of its portfolio in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 1,100 shares. Creative Planning invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Pnc Fin Service Group holds 0% or 20,021 shares in its portfolio. Moreover, United Capital Financial Advisers Lc has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 86,422 shares. First Manhattan reported 7,215 shares or 0% of all its holdings. California Pub Employees Retirement Systems invested in 78,800 shares or 0% of the stock. Neuberger Berman Grp Incorporated Limited Liability Company reported 46,176 shares or 0% of all its holdings. Royal Bankshares Of Canada has 21 shares for 0% of their portfolio. Bryn Mawr has 10,000 shares. Finemark Bancorp holds 0% or 22,589 shares. Leisure Cap holds 0.04% of its portfolio in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 64,067 shares. Deutsche State Bank Ag invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Two Sigma Securities Ltd Com holds 21,733 shares.

Among 3 analysts covering Ohr Pharma (NASDAQ:OHRP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Ohr Pharma had 6 analyst reports since August 7, 2015 according to SRatingsIntel. On Friday, August 7 the stock rating was maintained by Brean Capital with “Buy”. On Wednesday, August 10 the stock rating was downgraded by Brean Capital to “Hold”. H.C. Wainwright maintained it with “Buy” rating and $10.0 target in Wednesday, August 16 report. Roth Capital downgraded the shares of OHRP in report on Friday, January 5 to “Hold” rating. The firm has “Buy” rating given on Thursday, October 27 by H.C. Wainwright.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts